Actively Recruiting
Presynaptic Imaging in Major Depressive Episodes After COVID-19
Led by Centre for Addiction and Mental Health · Updated on 2026-02-11
90
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
CONDITIONS
Official Title
Presynaptic Imaging in Major Depressive Episodes After COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- New onset major depressive episode within 3 months after mild or moderate COVID-19, confirmed by a structured clinical interview
- Age between 18 and 75 years
- Good general physical health with no active medical conditions except migraine or post-acute sequelae of COVID-19 (PASC)
You will not qualify if you...
- Use of antidepressants within the previous month (6 weeks for fluoxetine)
- Use of stimulant medications affecting dopamine release within the previous month
- Use of antipsychotics within the previous month
- History of neurological disease except migraine or PASC
- Use of medications or herbal products with central nervous system effects within the past 2 weeks
- Cigarette smoking in the past 2 months
- Lifetime severe substance or alcohol use disorder or mild to moderate disorder in past 2 years
- Recreational drug use including marijuana in the past 2 months
- Positive urine drug or cotinine screen during the study
- History of psychotic symptoms before COVID-19 related to schizophrenia or bipolar disorder
- Current pregnancy or breastfeeding (for females)
- Disorders of coagulation or use of anticoagulant medication
- Claustrophobia
- Weight over 400 pounds or height over 7 feet
- Presence of metal implants or devices contraindicated for MRI
- Severe allergic reaction to alcohol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Actively Recruiting
Research Team
K
Karida Liu
CONTACT
J
Jeffrey Meyer
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here